UroGen Pharma (URGN) Stock Forecast, Price Target & Predictions

OverviewRevenue Ownership Financials Chart Transcripts

URGN Stock Forecast

UroGen Pharma stock forecast is as follows: an average price target of $38.60 (represents a 234.20% upside from URGN’s last price of $11.55) and a rating consensus of 'Buy', based on 9 wall street analysts offering a 1-year stock forecast.

URGN Price Target

The average price target for UroGen Pharma (URGN) is $38.60 based on 1-year price targets from 9 Wall Street analysts in the past 3 months, with a price target range of $60.00 to $22.00. This represents a potential 234.20% upside from URGN's last price of $11.55.

URGN Analyst Ratings

Buy

According to 9 Wall Street analysts, UroGen Pharma's rating consensus is 'Buy'. The analyst rating breakdown for URGN stock is 0 'Strong Buy' (0.00%), 7 'Buy' (77.78%), 2 'Hold' (22.22%), 0 'Sell' (0.00%), and 0 'Strong Sell' (0.00%).

UroGen Pharma Price Target by Analyst

Date	Analyst	Company	Price Target	Price when Published	Price Target/Price when Published	Price Target/Last Closing Price
Oct 14, 2024	Jason Kolbert	EF Hutton	$25.00	$12.60	98.41%	116.45%
Jun 14, 2024	Stephen Richardson	Evercore ISI	$46.00	$20.26	127.05%	298.27%
Jun 14, 2024	Leland Gershell	Oppenheimer	$40.00	$17.50	128.57%	246.32%
Jun 14, 2024	Raghuram Selvaraju	H.C. Wainwright	$60.00	$17.50	242.86%	419.48%
Jun 14, 2024	Paul Choi	Goldman Sachs	$22.00	$17.50	25.71%	90.48%
May 14, 2024	Leland Gershell	Oppenheimer	$32.00	$13.07	144.84%	177.06%
Mar 15, 2024	Leland Gershell	Oppenheimer	$34.00	$14.46	135.13%	194.37%
Dec 12, 2022	-	H.C. Wainwright	$23.00	$7.94	189.67%	99.13%

Row per page

Go to

The latest UroGen Pharma stock forecast, released on Oct 14, 2024 by Jason Kolbert from EF Hutton, set a price target of $25.00, which represents a 98.41% increase from the stock price at the time of the forecast ($12.60), and a 116.45% increase from URGN last price ($11.55).

UroGen Pharma Price Target by Period

	1M	3M	12M
# Anlaysts	-	1	7
Avg Price Target	-	$25.00	$37.00
Last Closing Price	$11.55	$11.55	$11.55
Upside/Downside	-100.00%	116.45%	220.35%

In the current month, the average price target of UroGen Pharma stock is -, according to 0 Wall Street analyst offering twelve months forecast. The average price target represents a -100.00% decrease as opposed to UroGen Pharma's last price of $11.55. This month's average price target is down -100.00% compared to last quarter, and down -100.00% compared to last year.

Analyst Ratings Upgrades/Downgrades

Date	Company	Previous Rating	New Rating	Rating Change
Oct 16, 2024	Oppenheimer	Outperform	Outperform	Hold
Oct 14, 2024	EF Hutton	-	Buy	Initialise
Oct 03, 2024	H.C. Wainwright	Buy	Buy	Hold
Sep 18, 2024	Oppenheimer	Outperform	Outperform	Hold
Aug 22, 2024	Guggenheim	-	Buy	Initialise
Aug 16, 2024	H.C. Wainwright	Buy	Buy	Hold
Jun 14, 2024	Benchmark	Buy	Buy	Hold
Jun 14, 2024	Keefe, Bruyette & Woods	-	Outperform	Upgrade
Jun 14, 2024	Stephens	Equal-Weight	Equal-Weight	Hold
Jun 14, 2024	Oppenheimer	Outperform	Outperform	Hold

Row per page

Go to

UroGen Pharma's last stock rating was published by Oppenheimer on Oct 16, 2024. The company gave URGN a "Outperform" rating, the same as its previous rate.

UroGen Pharma Financial Forecast

UroGen Pharma Revenue Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
Revenue	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$20.85M	$21.14M	$17.19M	$18.09M	$16.10M	$16.60M	$13.56M	$16.17M	$11.35M
Avg Forecast	$187.30M	$180.09M	$180.09M	$172.89M	$183.65M	$176.59M	$176.59M	$169.52M	$101.78M	$97.87M	$97.87M	$93.95M	$48.43M	$35.41M	$27.24M	$22.82M	$26.13M	$24.20M	$23.97M	$21.39M	$22.57M	$20.03M	$20.12M	$17.11M	$18.51M	$20.15M	$17.22M	$15.17M	$16.24M	$15.37M
High Forecast	$196.79M	$189.22M	$189.22M	$181.65M	$192.96M	$185.54M	$185.54M	$178.12M	$106.94M	$102.83M	$102.83M	$98.72M	$50.88M	$37.20M	$28.62M	$23.04M	$26.97M	$25.43M	$23.97M	$22.48M	$23.07M	$20.04M	$21.14M	$17.98M	$19.45M	$20.15M	$17.22M	$15.17M	$16.24M	$15.37M
Low Forecast	$180.41M	$173.47M	$173.47M	$166.54M	$176.90M	$170.10M	$170.10M	$163.29M	$98.04M	$94.27M	$94.27M	$90.50M	$46.65M	$34.11M	$26.24M	$22.60M	$25.28M	$23.31M	$23.97M	$20.60M	$22.06M	$20.03M	$19.38M	$16.48M	$17.83M	$20.15M	$17.22M	$15.17M	$16.24M	$15.37M
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	1	1	3	1	1	1	1	1	1	1	3	4
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	1.04%	1.05%	1.00%	0.98%	0.80%	0.96%	0.89%	1.00%	0.74%

UroGen Pharma's average Quarter revenue forecast for Dec 23 based on 3 analysts is $22.57M, with a low forecast of $22.06M, and a high forecast of $23.07M. URGN's average Quarter revenue forecast represents a 8.23% increase compared to the company's last Quarter revenue of $20.85M (Sep 23).

UroGen Pharma EBITDA Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	1	1	3	1	1	1	1	1	1	1	3	4
EBITDA	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-12.18M	$-15.38M	$-20.98M	$-19.88M	$-17.17M	$-18.11M	$-21.50M	$-27.97M	$-29.76M
Avg Forecast	$-178.74M	$-171.87M	$-171.87M	$-165.00M	$-175.27M	$-168.52M	$-168.52M	$-161.78M	$-97.14M	$-93.40M	$-93.40M	$-89.66M	$-46.22M	$-33.79M	$-25.99M	$-21.78M	$-24.94M	$-23.10M	$-22.87M	$-20.41M	$-21.54M	$-19.12M	$-19.20M	$-16.33M	$-17.67M	$-19.23M	$-16.44M	$-29.00	$-15.50M	$-14.66M
High Forecast	$-172.18M	$-165.55M	$-165.55M	$-158.93M	$-168.83M	$-162.33M	$-162.33M	$-155.84M	$-93.57M	$-89.97M	$-89.97M	$-86.37M	$-44.52M	$-32.55M	$-25.04M	$-21.57M	$-24.13M	$-22.25M	$-22.87M	$-19.66M	$-21.06M	$-19.12M	$-18.50M	$-15.73M	$-17.02M	$-19.23M	$-16.44M	$-23.00	$-15.50M	$-14.66M
Low Forecast	$-187.80M	$-180.58M	$-180.58M	$-173.36M	$-184.15M	$-177.07M	$-177.07M	$-169.98M	$-102.06M	$-98.13M	$-98.13M	$-94.21M	$-48.56M	$-35.50M	$-27.31M	$-21.99M	$-25.74M	$-24.27M	$-22.87M	$-21.45M	$-22.02M	$-19.12M	$-20.17M	$-17.16M	$-18.56M	$-19.23M	$-16.44M	$-35.00	$-15.50M	$-14.66M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.64%	0.80%	1.28%	1.13%	0.89%	1.10%	741482.76%	1.80%	2.03%

undefined analysts predict URGN's average Quarter EBITDA for undefined to be $NaN, with a high of $NaN and a low of $NaN. This is NaN% lower than UroGen Pharma's previous annual EBITDA (undefined) of $NaN.

UroGen Pharma Net Income Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	1	1	3	1	1	1	1	1	1	1	3	4
Net Income	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-21.88M	$-24.14M	$-30.21M	$-28.25M	$-25.83M	$-26.69M	$-28.39M	$-28.45M	$-30.21M
Avg Forecast	$49.41M	$48.51M	$49.54M	$40.35M	$43.95M	$43.38M	$44.54M	$42.48M	$21.52M	$21.90M	$23.28M	$21.34M	$-19.02M	$-28.57M	$-34.32M	$-34.66M	$-30.97M	$-35.22M	$-35.86M	$-37.35M	$-29.31M	$-36.46M	$-48.96M	$-57.32M	$-46.26M	$-42.59M	$-46.95M	$-30.00	$-43.27M	$-47.13M
High Forecast	$52.66M	$51.70M	$52.81M	$43.00M	$46.84M	$46.23M	$47.47M	$45.27M	$22.94M	$23.35M	$24.82M	$22.75M	$-18.11M	$-27.21M	$-32.68M	$-29.65M	$-27.20M	$-33.54M	$-34.15M	$-35.57M	$-26.68M	$-34.72M	$-46.62M	$-54.58M	$-44.05M	$-42.59M	$-46.95M	$-24.00	$-43.27M	$-47.13M
Low Forecast	$47.05M	$46.19M	$47.18M	$38.42M	$41.85M	$41.30M	$42.41M	$40.45M	$20.50M	$20.86M	$22.17M	$20.32M	$-20.28M	$-30.46M	$-36.58M	$-39.30M	$-34.32M	$-37.54M	$-38.22M	$-39.81M	$-30.62M	$-38.87M	$-52.19M	$-61.10M	$-49.31M	$-42.59M	$-46.95M	$-36.00	$-43.27M	$-47.13M
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.60%	0.49%	0.53%	0.61%	0.61%	0.57%	946400.00%	0.66%	0.64%

UroGen Pharma's average Quarter net income forecast for undefined is $NaN, with a range of $NaN to $NaN. URGN's average Quarter net income forecast represents a NaN% decrease compared to the company's last Quarter net income of $NaN (undefined).

UroGen Pharma SG&A Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	1	1	3	1	1	1	1	1	1	1	3	4
SG&A	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$21.75M	$22.49M	$24.47M	$21.63M	$19.07M	$20.83M	$21.30M	$87.53M	$21.62M
Avg Forecast	$125.72B	$120.89B	$120.89B	$116.05B	$123.28B	$118.54B	$118.54B	$113.79B	$68.32B	$65.69B	$65.69B	$63.07B	$32.51B	$23.77B	$18.28B	$15.32B	$17.54B	$16.25B	$16.09B	$14.36B	$15.15B	$13.45B	$13.51B	$11.49B	$12.43B	$13.52B	$11.56B	$22.00	$10.90B	$10.31B
High Forecast	$132.10B	$127.02B	$127.02B	$121.93B	$129.52B	$124.54B	$124.54B	$119.56B	$71.79B	$69.02B	$69.02B	$66.26B	$34.16B	$24.97B	$19.21B	$15.47B	$18.11B	$17.07B	$16.09B	$15.09B	$15.49B	$13.45B	$14.19B	$12.07B	$13.06B	$13.52B	$11.56B	$27.00	$10.90B	$10.31B
Low Forecast	$121.10B	$116.45B	$116.45B	$111.79B	$118.75B	$114.18B	$114.18B	$109.61B	$65.81B	$63.28B	$63.28B	$60.75B	$31.31B	$22.89B	$17.61B	$15.17B	$16.97B	$15.65B	$16.09B	$13.83B	$14.81B	$13.45B	$13.01B	$11.06B	$11.97B	$13.52B	$11.56B	$18.00	$10.90B	$10.31B
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.00%	0.00%	0.00%	0.00%	0.00%	0.00%	968181.82%	0.01%	0.00%

UroGen Pharma's average Quarter SG&A projection for Dec 23 is $15.15B, based on 3 Wall Street analysts, with a range of $14.81B to $15.49B. The forecast indicates a 69535.82% rise compared to URGN last annual SG&A of $21.75M (Sep 23).

UroGen Pharma EPS Forecast

	Dec 28	Sep 28	Jun 28	Mar 28	Dec 27	Sep 27	Jun 27	Mar 27	Dec 26	Sep 26	Jun 26	Mar 26	Dec 25	Sep 25	Jun 25	Mar 25	Dec 24	Sep 24	Jun 24	Mar 24	Dec 23	Sep 23	Jun 23	Mar 23	Dec 22	Sep 22	Jun 22	Mar 22	Dec 21	Sep 21
# Analysts	1	1	1	1	2	2	2	2	2	2	2	2	1	1	1	4	4	2	1	1	3	1	1	1	1	1	1	1	3	4
EPS	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	$-0.68	$-1.03	$-1.30	$-1.22	$-1.13	$-1.18	$-1.25	$-1.27	$-1.35
Avg Forecast	$1.15	$1.13	$1.15	$0.94	$1.02	$1.01	$1.03	$0.99	$0.50	$0.51	$0.54	$0.50	$-0.44	$-0.66	$-0.80	$-0.80	$-0.72	$-0.82	$-0.83	$-0.87	$-0.68	$-0.85	$-1.14	$-1.33	$-1.07	$-1.16	$-1.27	$-1.33	$-1.18	$-1.28
High Forecast	$1.22	$1.20	$1.23	$1.00	$1.09	$1.07	$1.10	$1.05	$0.53	$0.54	$0.58	$0.53	$-0.42	$-0.63	$-0.76	$-0.69	$-0.63	$-0.78	$-0.79	$-0.83	$-0.62	$-0.81	$-1.08	$-1.27	$-1.02	$-1.16	$-1.27	$-1.33	$-1.18	$-1.28
Low Forecast	$1.09	$1.07	$1.09	$0.89	$0.97	$0.96	$0.98	$0.94	$0.48	$0.48	$0.51	$0.47	$-0.47	$-0.71	$-0.85	$-0.91	$-0.80	$-0.87	$-0.89	$-0.92	$-0.71	$-0.90	$-1.21	$-1.42	$-1.14	$-1.16	$-1.27	$-1.33	$-1.18	$-1.28
Surprise %	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	-	0.80%	0.91%	0.98%	1.14%	0.98%	0.93%	0.94%	1.08%	1.05%

According to undefined Wall Street analysts, UroGen Pharma's projected average Quarter EPS for undefined is $NaN, with a low estimate of $NaN and a high estimate of $NaN. This represents a NaN% decrease compared to URGN previous annual EPS of $NaN (undefined).

UroGen Pharma Peer Comparison by Price Target

Ticker	Company	Last Closing Price	Avg Price Target	Upside/Downside	Avg Rating
XLO	Xilio Therapeutics	$0.92	$7.00	660.87%	Buy
OVID	Ovid Therapeutics	$1.06	$7.33	591.51%	Buy
PEPG	PepGen	$4.32	$29.50	582.87%	Buy
VACC	Barinthus Biotherapeutics	$5.00	$22.00	340.00%	-
VIGL	Vigil Neuroscience	$3.00	$11.00	266.67%	Buy
CMPX	Compass Therapeutics	$1.38	$5.00	262.32%	Buy
CCCC	C4 Therapeutics	$4.01	$13.50	236.66%	Buy
URGN	UroGen Pharma	$11.55	$38.60	234.20%	Buy
PRTC	PureTech Health	$21.78	$57.00	161.71%	Buy
ELYM	Eliem Therapeutics	$5.11	$13.00	154.40%	Buy
ERAS	Erasca	$2.60	$6.50	150.00%	Buy
CELC	Celcuity	$12.73	$31.50	147.45%	Buy
TYRA	Tyra Biosciences	$15.36	$31.75	106.71%	Buy
KRON	Kronos Bio	$0.87	$1.63	87.36%	Buy
ELVN	Enliven Therapeutics	$25.41	$39.50	55.45%	Buy
SRRK	Scholar Rock	$26.67	$40.50	51.86%	Buy
CNTB	Connect Biopharma	$0.99	$1.50	51.52%	Buy
EWTX	Edgewise Therapeutics	$31.98	$45.00	40.71%	Buy
IKNA	Ikena Oncology	$1.73	$1.33	-23.12%	Buy

URGN Forecast FAQ

Is UroGen Pharma a good buy?

Yes, according to 9 Wall Street analysts, UroGen Pharma (URGN) is considered a 'Buy'. The rating consensus is based on 0 'Strong Buy' and 7 'Buy' recommendations, accounting for 77.78% of URGN's total ratings.

What is URGN's price target?

UroGen Pharma (URGN) average price target is $38.6 with a range of $22 to $60, implying a 234.20% from its last price of $11.55. The data is based on 9 Wall Street analysts who provided a twelve-month price target estimate in the last three months.

Will UroGen Pharma stock go up soon?

According to Wall Street analysts' prediction for URGN stock, the company can go up by 234.20% (from the last price of $11.55 to the average price target of $38.6), up by 419.48% based on the highest stock price target, and up by 90.48% based on the lowest stock price target.

Can UroGen Pharma stock reach $20?

URGN's average twelve months analyst stock price target of $38.6 supports the claim that UroGen Pharma can reach $20 in the near future.

What are UroGen Pharma's analysts' financial forecasts?

UroGen Pharma's analysts financial forecasts for the fiscal year (Dec 2027) are as follows: average revenue is $706.35M (high $742.15M, low $680.39M), average EBITDA is $-674M (high $-649M, low $-708M), average net income is $174.34M (high $185.82M, low $166.01M), average SG&A $474.14B (high $498.17B, low $456.72B), and average EPS is $4.04 (high $4.31, low $3.85). URGN's analysts financial forecasts for the fiscal year (Dec 2028) are as follows: average revenue is $720.37M (high $756.88M, low $693.9M), average EBITDA is $-687M (high $-662M, low $-722M), average net income is $187.8M (high $200.18M, low $178.83M), average SG&A $483.55B (high $508.06B, low $465.78B), and average EPS is $4.36 (high $4.64, low $4.15).

Did the URGN's actual financial results beat the analysts' financial forecasts?

Based on UroGen Pharma's last annual report (Dec 2023), the company's revenue was $82.71M, beating the average analysts forecast of $79.83M by 3.61%. Apple's EBITDA was $-65.536M, missing the average prediction of $-76.188M by -13.98%. The company's net income was $-102M, missing the average estimation of $-172M by -40.58%. Apple's SG&A was $93.27M, missing the average forecast of $53.59B by -99.83%. Lastly, the company's EPS was $-0.0035, missing the average prediction of $-3.992 by -99.91%. In terms of the last quarterly report (Sep 2023), UroGen Pharma's revenue was $20.85M, beating the average analysts' forecast of $20.03M by 4.08%. The company's EBITDA was $-12.179M, missing the average prediction of $-19.12M by -36.30%. UroGen Pharma's net income was $-21.879M, missing the average estimation of $-36.463M by -40.00%. The company's SG&A was $21.76M, missing the average forecast of $13.45B by -99.84%. Lastly, the company's EPS was $-0.68, missing the average prediction of $-0.846 by -19.62%